Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
about
Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantationInterventions for treatment of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantationInterventions for prophylaxis of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantationAdvancements in the treatment of pediatric acute leukemia and brain tumor - continuous efforts for 100% cureHepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies.Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.Fatal and unanticipated cardiorespiratory disease in a two-year-old child with hurler syndrome following successful stem cell transplant.Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.Imaging of acute and subacute toxicities of cancer therapy in children.Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation.HLA, GVHD, and parenteral nutrition are risk factors for hepatic complications in pediatric HSCT.Safety of peritoneal and pleural drain placement in pediatric stem cell transplant recipients with severe veno-occlusive disease.Emergence of CD43-Expressing Hematopoietic Progenitors from Human Induced Pluripotent Stem Cells.The Myeloablative Drug Busulfan Converts Cysteine to Dehydroalanine and Lanthionine in Redoxins.The busulfan metabolite EdAG irreversibly glutathionylates glutaredoxins.Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome.Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.Successful treatment of hepatic sinusoidal obstructive syndrome after hematopoietic stem cell transplantation in a child using recombinant thrombomodulin.Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant.Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.Using liver elastography to diagnose sinusoidal obstruction syndrome in pediatric patients undergoing hematopoetic stem cell transplant.Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients.Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation.Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure
P2860
Q24187812-CD1C04C2-8BBE-4C46-AAD5-CF51E7E118C8Q24234682-5AA4EB2B-90D1-4D5E-AF6F-FF37D52E1029Q24234757-2F314DAE-49E9-4405-B6AA-D02299A6BDC3Q27027799-56DA2726-32B3-4ED4-A800-A9C1E3F06041Q34479575-052EC2FC-EBEF-4803-9A43-CD8D7D31FBBCQ35029393-DDD5EE85-A7F5-431F-B928-3274133CA2ACQ36264751-4EDFC3DD-3A75-49D7-9594-F4EFBB93E52BQ37127672-1537D311-8132-4DF8-A84B-9BD714A17DC7Q37292304-6441FDA1-2D41-4BE4-ADE5-71F5A3FD06A1Q38025158-EC7290FD-E744-46C3-A3F5-328412C1C0C4Q38605263-7A41E0C1-7E9D-4A04-8327-4BDD5D0D69C5Q38616218-46CF00B1-E173-4EF9-A066-01DF6B62176FQ39404864-9DA03F17-69DD-4BE0-AB82-7E0EDC11E729Q40170434-75BAD337-2241-4469-A044-68A968927C86Q40373921-27D90ADB-44C3-49AC-A3EA-04398D9CAFF1Q40627070-0D5F6D6C-945F-42D9-8AAB-70954FE86DB1Q41813455-C256CC94-DC78-447C-ACB7-914EBF427E24Q42086998-8F18792C-44AF-46F8-A69F-12EF9DC579CDQ42233328-916657E3-F4B2-4C9D-8807-B6692D6DD4FCQ43221658-DF0CBBF8-C52F-4B4F-9415-DCD753FEC7FFQ43551135-6A6BCD8B-3774-4604-95DC-132AABE7E457Q43669738-092BB9D6-CFE2-4D3B-9E98-04EB7CB7F0ABQ45067466-4A3EE0E1-BA15-48D5-9A94-38CEC51E7468Q45122639-9B9C34C4-2818-48DD-9896-DF53E271505DQ46316908-E98D109B-E953-4C28-9A26-94EA9D8A8527Q46512727-F01A1937-87A8-4E4D-B732-737EC8791CB5Q48239384-A1E8954F-AE85-4964-88F6-3DF96DEE2131Q49276207-28F1F664-1BC2-491C-B443-ABD951276EAFQ53580759-8D351CC3-B4D7-43DD-A478-110B84AA503CQ54187733-D63CF93E-349A-43DB-8B59-CE9C8779A53BQ57301971-CB8A8A6B-03F8-4206-8C17-78F47F251B31
P2860
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Incidence, survival and risk f ...... em cell transplant recipients.
@ast
Incidence, survival and risk f ...... em cell transplant recipients.
@en
type
label
Incidence, survival and risk f ...... em cell transplant recipients.
@ast
Incidence, survival and risk f ...... em cell transplant recipients.
@en
prefLabel
Incidence, survival and risk f ...... em cell transplant recipients.
@ast
Incidence, survival and risk f ...... em cell transplant recipients.
@en
P2093
P356
P1476
Incidence, survival and risk f ...... tem cell transplant recipients
@en
P2093
P2888
P356
10.1038/SJ.BMT.1704069
P407
P577
2003-07-01T00:00:00Z